Testosterone metabolism and formation of cytosol 5α-dihydrotestosterone-receptor complex in the rat prostate in vitro: Effects of lindane and malathion

1992 ◽  
Vol 6 (3) ◽  
pp. 267-271
Author(s):  
B. Šimić ◽  
D. Bogojević ◽  
S. Trikić ◽  
J. Kniewald
1969 ◽  
Vol 44 (3) ◽  
pp. 323-333 ◽  
Author(s):  
W. I. P. MAINWARING

SUMMARY The specificity of the binding of [1,2-3H]testosterone to nuclei of various rat tissues in vivo has been studied. A significant amount of radioactivity was retained in the nuclei of androgen-dependent tissues only, particularly the ventral prostate gland. The bound radioactivity was only partially recovered as [1,2-3H]testosterone; the remainder was identified as [3H]5α-dihydrotestosterone. Efforts were made to characterize the binding component, or 'receptor', in prostatic nuclei. On digestion of nuclei labelled in vivo with [1,2-3H]testosterone, with enzymes of narrow substrate specificity, only trypsin released tritium, suggesting that the receptor is a protein. On the basis of subfractionation studies of labelled nuclei, the receptor is an acidic protein. The androgen—receptor complex could be effectively extracted from the prostatic nuclei in 1 m-NaCl and from the results of fractionations on a calibrated agarose column, the complex has a molecular weight 100,000–120,000. The specificity of the binding of steroids to such 1 m-NaCl extracts in vitro was investigated by the equilibrium dialysis procedure. Under these conditions, the specificity of the binding of [1,2-3H]testosterone demonstrated in vivo could not be simulated. The receptor is probably part of the chromatin complex but its precise intranuclear localization cannot be determined by biochemical procedures alone.


1973 ◽  
Vol 51 (6) ◽  
pp. 735-740 ◽  
Author(s):  
D. K. H. Lee ◽  
J. C. Young ◽  
Y. Tamura ◽  
D. C. Patterson ◽  
C. E. Bird ◽  
...  

The inhibitory effects of six estrogens (estradiol, estriol, ethynylestradiol, mestranol, diethylstilbestrol, and chlorotrianisene) on testosterone Δ4-reduction were studied in rat prostate and liver preparations. In the prostate homogenates only those estrogens with a complete steroid structure and a free phenolic hydroxyl group at position 3 of the steroid nucleus inhibited testosterone 5α-reduction when present at 600 times the concentration of testosterone. The inhibition by estradiol was found to be competitive for prostate homogenate, microsomal, and nuclear preparations. In the liver preparations (homogenate, microsomal, and soluble fractions) all six estrogens inhibited significantly when present at the same concentration as testosterone; diethylstilbestrol and ethynylestradiol were the most effective ones.


Andrologia ◽  
2009 ◽  
Vol 19 (2) ◽  
pp. 188-192 ◽  
Author(s):  
A.R. SHETH ◽  
R. JOSEPH ◽  
A. MAITRA

1986 ◽  
Vol 25 ◽  
pp. 77
Author(s):  
D. Beerens ◽  
H.-C. Coene ◽  
V. Dergent ◽  
R. De Coster

1998 ◽  
Vol 16 (5) ◽  
pp. 433-442 ◽  
Author(s):  
Leonardo Pignataro ◽  
Alejandro A.Colman Lerner ◽  
J.Lino Barañao ◽  
Sara Fiszer De Plazas

Planta Medica ◽  
2012 ◽  
Vol 78 (11) ◽  
Author(s):  
HM Lee ◽  
TG Ahn ◽  
CW Kim ◽  
HJ An
Keyword(s):  

1990 ◽  
Vol 64 (03) ◽  
pp. 402-406 ◽  
Author(s):  
M D Oethinger ◽  
E Seifried

SummaryThe present in vitro study investigated dose-, time- and temperature-dependent effects of two-chain urokinase plasminogen activato(u-PA, urokinase) on normal citrated plasma. When 10 μg/ml u-PA wereadded to pooled normal plasma and incubated for 30 min at an ambient temperature (25° C), α2-antiplas-min decreased to 8% of the control value. Incubation on ice yielded a decrease to 45% of control,whereas α2-antiplasmin was fully consumed at 37° C. Fibrinogen and plasminogen fell to 46% and 39%, respectively, after a 30 min incubation at 25° C. Thrombin time prolonged to 190% of control.Various inhibitors were studied with respect to their suitability and efficacy to prevent these in vitro effects. Aprotinin exhibited a good protective effect on fibrinogen at concentrations exceeding 500 KlU/ml plasma. Its use, however, was limited due to interferences with some haemostatic assays. We could demonstrate that L-Glutamyl-L-Glycyl-L-Arginyl chloromethyl ketone (GGACK) and a specific polyclonal anti-u-PA-antibody (anti-u-PA-IgG) effectively inhibited urokinase-induced plasmin generation without interfering with haemostatic assays. The anti-u-PA-antibody afforded full protection ofα2-antiplasmin at therapeutic levels of u-PA.It is concluded that u-PA in plasma samples from patients during thrombolytic therapy may induce in vitro effects which should be prevented by the use of a suitable inhibitor such as GGACK or specific anti-u-PA-antibody.


Sign in / Sign up

Export Citation Format

Share Document